<ion-content>
    <ion-card>
            <ion-card-header color="primary" text-center>
                Type I
            </ion-card-header>
            <ion-card-content>
                Amikacin
            </ion-card-content>
        </ion-card>
        <ion-card>
            <ion-card-header color="primary" text-center>
                Type II
            </ion-card-header>
            <ion-card-content>
                Cefoperazone / Sulbactam
                <span class="cardCustom"> (or)</span>
                Piperacillin / Tazobactam
            </ion-card-content>
        </ion-card>
        <ion-card>
            <ion-card-header color="primary" text-center>
                Type III
            </ion-card-header>
            <ion-card-content>
                Meropenem + / - Amikacin
                <span class="cardCustom"> (or)</span>
                Imipenem + / - Amikacin
            </ion-card-content>
        </ion-card>
        <ion-card>
            <ion-card-header color="primary" text-center>
                Type IV
            </ion-card-header>
            <ion-card-content>
                Based on IDSA Guildelines and risk factors empirical antifungal Flucanazole can be added if candida infection is suspected in Febrile Neutropenic patients
            </ion-card-content>
        </ion-card>
        <ion-card>
            <ion-card-header color="danger">
                NOTE :
            </ion-card-header>
            <ion-card-content>
                1. Renal Function to be assessed if INJ.Amikacin is to be continued<br>
                2. Vancomycin or Linezolid if MRSA is suspected<br>
                3. Metronidazole can be added if anaerobic cover of antibiotics is not adequate<br>
            </ion-card-content>
        </ion-card>
</ion-content>